Similarly in line with our results, PI3K inhibitor sensitivity across a panel of breast cancer cell lines was predicted by responsiveness to the ERBB3 ligand heregulin much better than by pAKT expression level or PIK3CA mutations [19]. This evidence concerns the gene ERBB3 and breast cancer.